首页> 外文期刊>Journal of managed care pharmacy : >Core Management Principles in Rheumatoid Arthritis to Help Guide Managed Care Professionals
【24h】

Core Management Principles in Rheumatoid Arthritis to Help Guide Managed Care Professionals

机译:类风湿关节炎的核心管理原则,以帮助指导管理式护理专业人员

获取原文
获取原文并翻译 | 示例
       

摘要

BACKGROUND: Rheumatoid arthritis (RA) is a chronic, systemic autoimmune inflammatory disease that affects approximately 1% of the population. Initial symptoms include joint swelling, stiffness, and tenderness, which are all causes of disability. The diagnosis of RA is based on patient history of joint pain and stiffness, the documentation of symmetric poly-articular joint synovitis, and laboratory measures including radiographs, inflammatory markers, and autoantibodies. As the disease progresses, synovia! inflammation leads to cartilage damage, bone erosions, and joint destruction, the major causes of long-term disability. RA is associated with many comorbidities and complications, including cardiovascular disease, which is responsible for higher rates of mortality among patients compared with the general population. Over the past 2 decades, advances in the development of synthetic disease-modifying antirheumatic drugs (DMARDs) and biologic agents for RA have markedly changed treatment goals and management strategies.
机译:背景:类风湿关节炎(RA)是一种慢性全身性自身免疫性炎性疾病,大约占总人口的1%。最初的症状包括关节肿胀,僵硬和压痛,这些都是导致残疾的原因。 RA的诊断基于患者的关节痛和僵硬病史,对称性多关节关节滑膜炎的文献记录以及包括X线照片,炎症标记和自身抗体在内的实验室检查。随着疾病的进展,滑膜炎!炎症导致软骨损伤,骨侵蚀和关节破坏,这是长期残疾的主要原因。 RA与许多合并症和并发症(包括心血管疾病)相关,与一般人群相比,RA导致患者的死亡率更高。在过去的20年中,用于RA的合成疾病修饰抗风湿药(DMARD)和生物制剂的开发进展显着改变了治疗目标和管理策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号